Trials / Completed
CompletedNCT01769716
Umbilical Cord Blood Therapy for Global Developmental Delay
Umbilical Cord Blood Therapy for Children With Global Developmental Delay
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- MinYoung Kim, M.D. · Academic / Other
- Sex
- All
- Age
- 6 Months – 15 Years
- Healthy volunteers
- Not accepted
Summary
This open-label study aims to evaluate the safety and efficacy of autologous or allogeneic umbilical cord blood therapy for children with global developmental delay.
Detailed description
Global developmental delay is defined as significant delay in two or more of the following developmental domains: gross/fine motor, speech/language, cognition, social/personal, and activities of daily living. Umbilical cord blood has been used for inherited metabolic diseases that feature global developmental delay and many experimental animal studies have revealed umbilical cord blood is useful to repair neurological impairments in brain.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Umbilical cord blood transplantation |
Timeline
- Start date
- 2012-12-01
- Primary completion
- 2017-12-01
- Completion
- 2017-12-01
- First posted
- 2013-01-17
- Last updated
- 2018-01-23
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01769716. Inclusion in this directory is not an endorsement.